GH Research (GHRS) Retained Earnings (2021 - 2026)
GH Research (GHRS) posted quarterly Retained Earnings of -$154.4 million for Q4 2025, down 45.07% year-over-year from -$281.1 million in Q4 2024, and down 10.08% quarter-over-quarter from -$140.3 million in Q3 2025.
GH Research (GHRS) Retained Earnings (2021 - 2026) Analysis & Trends
GH Research's Retained Earnings history runs 5 years deep, the most recent figure standing at -$154.4 million for Q4 2025.
- In Q4 2025, Retained Earnings fell 45.07% year-over-year to -$154.4 million; the TTM figure through Dec 2025 stood at -$154.4 million (down 45.07% YoY), while the FY2025 annual figure was -$154.4 million, down 45.07% from the prior year.
- Retained Earnings for Q4 2025 stood at -$154.4 million, down from -$140.3 million in the prior quarter.
- The five-year high for Retained Earnings was $291.5 million in Q4 2023, with the low at -$154.4 million in Q4 2025.
- The 5-year median for Retained Earnings is -$53.9 million (2023), against an average of -$47.4 million.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings plunged 552.99% in 2022, then surged 997.0% in 2023.
- GH Research's Retained Earnings stood at -$5.0 million in 2021, then slumped by 552.99% to -$32.5 million in 2022, then soared by 997.0% to $291.5 million in 2023, then plunged by 136.52% to -$106.4 million in 2024, then slumped by 45.07% to -$154.4 million in 2025.
- Business Quant data shows GHRS's Retained Earnings at -$154.4 million in Q4 2025, -$140.3 million in Q3 2025, and -$126.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | 542.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 542.67 Mn |
| Dec 31, 2025 | -154.43 Mn |
| Sep 30, 2025 | -140.29 Mn |
| Jun 30, 2025 | -126.27 Mn |
| Mar 31, 2025 | -117.04 Mn |
| Dec 31, 2024 | -106.45 Mn |
| Sep 30, 2024 | -97.64 Mn |
| Jun 30, 2024 | -85.56 Mn |
| Mar 31, 2024 | -75.51 Mn |
| Dec 31, 2023 | 291.46 Mn |
| Sep 30, 2023 | -56.67 Mn |
| Jun 30, 2023 | -51.16 Mn |
| Mar 31, 2023 | -43.43 Mn |
| Dec 31, 2022 | -32.49 Mn |
| Sep 30, 2022 | -15.91 Mn |
| Jun 30, 2022 | -15.47 Mn |
| Mar 31, 2022 | -15.80 Mn |
| Dec 31, 2021 | -4.98 Mn |
| Sep 30, 2021 | -5.95 Mn |